Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Professor; Intramural Faculty, Koch Institute

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.





Paul Thompson



Assistant Phone


  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.


  • Forbeck Fellow, 2015

Recent Publications

  1. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Zagorulya, M, Yim, L, Morgan, DM, Edwards, A, Torres-Mejia, E, Momin, N, McCreery, CV, Zamora, IL, Horton, BL, Fox, JG et al.. 2023. Immunity 56, 386-405.e10.
    doi: 10.1016/j.immuni.2023.01.010PMID:36736322
  2. MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Chatterjee, F, Spranger, S. 2023. Semin Immunol 66, 101710.
    doi: 10.1016/j.smim.2023.101710PMID:36640616
  3. Something old, something new: The marriage of PD-1 and IL-2. Horton, BL, Spranger, S. 2023. Immunity 56, 8-10.
    doi: 10.1016/j.immuni.2022.12.012PMID:36630920
  4. Once upon a prime: DCs shape cancer immunity. Zagorulya, M, Spranger, S. 2023. Trends Cancer 9, 172-184.
    doi: 10.1016/j.trecan.2022.10.006PMID:36357313
  5. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Sengupta, S, Das, S, Crespo, AC, Cornel, AM, Patel, AG, Mahadevan, NR, Campisi, M, Ali, AK, Sharma, B, Rowe, JH et al.. 2022. Nat Cancer 3, 1228-1246.
    doi: 10.1038/s43018-022-00427-5PMID:36138189
  6. Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies. Lutz, EA, Agarwal, Y, Momin, N, Cowles, SC, Palmeri, JR, Duong, E, Hornet, V, Sheen, A, Lax, BM, Rothschilds, AM et al.. 2022. Proc Natl Acad Sci U S A 119, e2205983119.
    doi: 10.1073/pnas.2205983119PMID:36037341
  7. Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. Fessenden, TB, Stopfer, LE, Chatterjee, F, Zulueta, J, Mesfin, J, Cordero Dumit, T, Reijers, I, Hoefsmit, EP, Blank, C, White, F et al.. 2022. J Immunother Cancer 10, .
    doi: 10.1136/jitc-2021-004159PMID:35820727
  8. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Jaeger, AM, Stopfer, LE, Ahn, R, Sanders, EA, Sandel, DA, Freed-Pastor, WA, Rideout, WM 3rd, Naranjo, S, Fessenden, T, Nguyen, KB et al.. 2022. Nature 607, 149-155.
    doi: 10.1038/s41586-022-04839-2PMID:35705813
  9. Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Wang, C, Cui, A, Bukenya, M, Aung, A, Pradhan, D, Whittaker, CA, Agarwal, Y, Thomas, A, Liang, S, Amlashi, P et al.. 2021. Cell Rep 37, 110021.
    doi: 10.1016/j.celrep.2021.110021PMID:34818534
  10. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Duong, E, Fessenden, TB, Lutz, E, Dinter, T, Yim, L, Blatt, S, Bhutkar, A, Wittrup, KD, Spranger, S. 2022. Immunity 55, 308-323.e9.
    doi: 10.1016/j.immuni.2021.10.020PMID:34800368
More Publications



Photo credit: Kelsey Montgomery